Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619172 | 1.00 | ACE (0.55) | ACECTSLTACR1NPC1RAB9A | |
| SCHEMBL7615303 | 0.92 | ACE (0.56) | ACECTSLTACR1CTSK | |
| SCHEMBL3696924 | 0.92 | ACE (0.56) | ACECTSLTACR1CTSK | |
| SCHEMBL3702371 | 0.89 | POLB (0.45) | ACETACR1PPARGPPARACTSK | |
| SCHEMBL7614061 | 0.89 | POLB (0.45) | ACETACR1PPARGPPARACTSK | |
| SCHEMBL3695626 | 0.89 | ACE (0.49) | ACETACR1NPC1RAB9APPARA | |
| SCHEMBL7614035 | 0.89 | ACE (0.49) | ACETACR1NPC1RAB9APPARA | |
| SCHEMBL7610226 | 0.87 | RAB9A (0.48) | CTSLNPC1RAB9APRSS1CTSG | |
| SCHEMBL3692412 | 0.87 | RAB9A (0.48) | CTSLNPC1RAB9APRSS1CTSG | |
| SCHEMBL3697165 | 0.85 | TACR1 (0.44) | ACECTSLTACR1RAB9APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8624052-B2 | S-t-butyl protected cysteine di-peptide analogs and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2638005-A2 | S-T-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012065102-A2 | S-T-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121202-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | ACE 1727/4885CTSL 112/4885TACR1 451/4885 |
| US-20120122792-A1 | S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDS | CSTB, IAPP, VIP | ACE 1727/4885CTSL 112/4885TACR1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.